Clinical Trial Update: Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on sequential CD19 and CD22-targeted CAR-T therapy for relapsed/refractory B cell lymphoma across Phase 1 and Phase 2 to evaluate safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell

Drugs mentioned

• CD19- and CD22-targeted CAR-T therapy

Snippet

Sponsor: Kecellitics Biotech Company Ltd | Conditions: Lymphoma, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN